home / stock / oyst / oyst news

OYST News and Press, Oyster Point Pharma Inc. From 02/16/22

Stock Information
Company Name: Oyster Point Pharma Inc.
Stock Symbol: OYST
Market: NASDAQ
Website: oysterpointrx.com
Menu
OYST OYST Quote OYST Short OYST News OYST Articles OYST Message Board
Get OYST Alerts

News, Short Squeeze, Breakout and More Instantly...
OYST - Oyster Point Pharma To Report Fourth Quarter And Full Year 2021 Financial Results On February 24, 2022

PRINCETON, N.J., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that...
OYST - Oyster Point Pharma to Present at Upcoming Investor Conferences in January 2022

PRINCETON, N.J., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, ...

OYST - Oyster Point Pharma set to join Nasdaq Biotechnology Index

Oyster Point Pharma (NASDAQ:OYST) announces its addition to Nasdaq Biotechnology Index, effective prior to market open on Dec. 20, 2021. It's a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapie...

OYST - Oyster Point Pharma Announces Addition To Nasdaq Biotechnology Index

PRINCETON, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that...
OYST - Oyster Point Pharma to Participate in the Piper Sandler 33rd Annual Healthcare Conference

PRINCETON, N.J., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, ...

OYST - Oyster Point Pharma Announces Publication in Ophthalmology of ONSET-2 Phase 3 Data on TYRVAYA?? (varenicline solution) Nasal Spray

PRINCETON, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), ("Oyster Point Pharma" or "the Company") a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ...

OYST - Oyster Point Pharma to Present Data at the American Academy of Ophthalmology Annual Meeting 2021

PRINCETON, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced mult...
OYST - Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q3 2021 Results - Earnings Call Transcript

Oyster Point Pharma, Inc. (OYST) Q3 2021 Earnings Conference Call November 4, 2021, 04:30 PM ET Company Participants Daniel Lochner - CFO Jeffrey Nau - President, CEO & Director John Snisarenko - Chief Commercial Officer Conference Call Participants Ken Cacciatore - Cowen Joe Catanzaro - ...

OYST - Oyster Point Pharma, Inc. (OYST) Q3 2021 Earnings Call Transcript

Image source: The Motley Fool. Oyster Point Pharma, Inc. (NASDAQ: OYST) Q3 2021 Earnings Call Nov 04, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Oyster Point Pharma, Inc. (OYST) Q3 2021 Earnings Call Transcript...

OYST - Oyster Point Pharma EPS beats by $0.48

Oyster Point Pharma (NASDAQ:OYST): Q3 GAAP EPS of -$0.68 beats by $0.48. Revenue of $17.94M Press Release As of September 30, 2021, cash and cash equivalents were $184.2M, compared to $192.6M as of December 31, 2020. For further details see: Oyster Point Pharma EPS beats by $0.48 ...
Previous 10 Next 10